← Back to patent-cliff list
贝美前列素/马来酸噻吗洛尔
Tier C — Watch / tradeBimatoprost/Timolol Maleate
艾尔建
Originator
2006
First approval
-
Expiry (public)
$0.58B ▲
Peak sales
化学药
Type
Targets：β-adrenoceptors、Prostanoid receptor
Brand：Ganfort
Indications (approved)：高眼压、开角型青光眼
Regional status
US
无进展
2001-08-01
EU
批准上市
2006-05-19
China
批准上市
2013-09-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bimatoprost/Timolol Maleate?
Approved indications include: 高眼压, 开角型青光眼.
When does the Bimatoprost/Timolol Maleate patent expire?
No public expiry year is available for Bimatoprost/Timolol Maleate yet; this page updates once verified.
How do I get a quote for Bimatoprost/Timolol Maleate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24